2012-09-17 05:59:01 - New Pharmaceuticals market report from Global Markets Direct: "Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012"

Global Markets Direct's, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012', provides an overview of the Metastatic Renal Cell Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma. 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered

based on the availability and relevance of data for the indicated disease.


Full Report Details at
- www.fastmr.com/prod/463770_metastatic_renal_cell_carcinoma_pipel ..


Scope

* A snapshot of the global therapeutic scenario for Metastatic Renal Cell Carcinoma.
* A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Metastatic Renal Cell Carcinoma therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Metastatic Renal Cell Carcinoma Therapeutic Products under Development, Key Players in Metastatic Renal Cell Carcinoma Therapeutics, Metastatic Renal Cell Carcinoma Pipeline Overview, Metastatic Renal Cell Carcinoma Pipeline, Metastatic Renal Cell Carcinoma Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Renal Cell Carcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma Therapeutics under Development by Companies
Metastatic Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Renal Cell Carcinoma Therapeutics - Products under Development by Companies
Metastatic Renal Cell Carcinoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Renal Cell Carcinoma Therapeutics Development
Bristol-Myers Squibb Company
Amgen Inc.
Eli Lilly and Company
Novartis AG
Eisai Co., Ltd.
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
Novartis Pharmaceuticals Corporation
Bionomics Limited
Angiogene Pharmaceuticals Ltd.
Cerulean Pharma, Inc.
AVEO Pharmaceuticals, Inc.
Abramson Cancer Center
Metastatic Renal Cell Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E7080 - Drug Profile
Afinitor - Drug Profile
IMC-1121B - Drug Profile
ZD6126 - Drug Profile
BNC105P + Afinitor - Drug Profile
Dalteparin + SU11248 - Drug Profile
LBH589 + RAD001 - Drug Profile
Sunitinib + Gemcitabine - Drug Profile
Tarceva + Rapamune - Drug Profile
Avastin - Drug Profile
Sutent - Drug Profile
OSI-774 - Drug Profile
Tivozanib + Torisel - Drug Profile
CVX 060 - Drug Profile
AMG 386 + Sunitinib - Drug Profile
Bevacizumab + Everolimus - Drug Profile
PEG Intron + Sargramostim + Thalidomide - Drug Profile
PEG Intron + Sargramostim + Thalidomide - Drug Profile
PEG Intron + Sargramostim + Thalidomide - Drug Profile
Gemcitabine + CPT-11 - Drug Profile
Pazopanib - Drug Profile
Enzastaurin + Sunitinib - Drug Profile
Sorafenib - Drug Profile
Capecitabine + Gemcitabine + Bevacizumab - Drug Profile
BAY 43-9006 - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463770&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.